Type 2 Diabetes Trial, Recruiting NCT07065383 Sponsor: University of Aberdeen Condition: Type 2 Diabetes
Back to Type 2 Diabetes

Type 2 Diabetes Trial, Recruiting

NCT07065383
Recruiting Not Applicable

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • People who have been diagnosed with type 2 diabetes within the last 10 years and are between 20 and 75 years old
  • People whose blood sugar control (measured by a test called HbA1c) is at a certain level (7% or above), generally managed with diet and/or certain common diabetes tablets — but not insulin
  • People who currently do less than 150 minutes per week of moderate to vigorous physical activity (such as brisk walking or jogging)
  • People with a BMI of 27 or above, and a body weight under 140kg (due to the weight limit of the scanning equipment used in the trial)
  • People whose kidneys are working at a level above a certain threshold, based on a blood test result within the last 3 months (confirm with trial site)
  • People who can read and understand written and spoken English

Who may not be able to join:

  • People with a previously unknown heart condition (other than mild valve issues)
  • People with a known history of heart disease, including heart attacks
  • People with an untreated or relevant hormonal condition (such as Cushing's syndrome)
  • People whose kidneys are not functioning above the required threshold based on a specific blood test result
  • People with a blood pressure reading above 180/100 mmHg
  • People taking certain medications that affect blood sugar or fat metabolism, such as niacin, omega-3 fatty acid supplements, or certain other diabetes injections
  • People following specific dietary patterns that may interfere with the study, such as a high-fat vegan diet (confirm with trial site for other diets)
  • People with a medical or surgical history that, in the investigators' judgement, may interfere with an exercise programme, affect fat metabolism, or raise safety concerns (such as circulatory problems in the legs, arthritis, certain neurological conditions, or fat storage disorders)
  • People with a known sensitivity or allergy to the study medication Semaglutide, or who have a history of diabetic eye disease, pancreatitis, or any cancer — or who are pregnant
  • People with significant asthma or lung disease
  • People who are unable to ride a stationary exercise bike
  • People who are unable to complete exercise testing, for example due to prosthetic limbs
  • People who are pregnant, breastfeeding, or planning to become pregnant
  • People who have recently had certain medical imaging involving contrast dye or radioactive materials (confirm with trial site on timing)
  • People who are unable to lie flat or stay still for scanning procedures
  • People whose body size does not fit within the MRI scanner (the trial site uses a physical hoop to check this)
  • People who do not feel able or motivated to commit to a physical training programme
  • People currently taking part in another interventional clinical trial
  • People who are not able to understand written or spoken English

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 20 July 2026
This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Principal Investigator: Dana Dawson, DM, University of Aberdeen

Phone: +441224559573

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Not Applicable
Sponsor
University of Aberdeen
Registry
ClinicalTrials.gov
Start date
1 August 2025
Est. completion
31 July 2028

Where this trial is recruiting

🇬🇧 United Kingdom

Primary endpoints

1H-magnetic resonance spectroscopy

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 20 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov